CommercialPrior AuthHigh impact
Omalizumab (CPB 0670, reviewed 2026-06-05)
Aetna·Allergy & Immunology, Pulmonology, ENT (Ear, Nose & Throat) +4 more·Medical Policy
Effective date
Jun 5, 2026
We identified it
Aug 12, 2026
Summary
Aetna updated its Clinical Policy Bulletin (CPB 0670) for omalizumab (Xolair and Omlyclo biosimilar) effective June 5, 2026, establishing comprehensive medical necessity criteria across five indications: moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, IgE-mediated food allergy, immune checkpoint inhibitor-related toxicity, and systemic mastocytosis. The policy mandates precertification for all omalizumab products through specialty pharmacy channels and requires specific prescriber specialties based on indication.
Action Required
REQUIREMENTS:
By June 5, 2026 (Policy Effective Date):
- Billing team must implement precertification requirements for ALL omalizumab products (Xolair and Omlyclo). Update billing software to automatically route omalizumab claims to specialty pharmacy precertification at (866) 752-7021 or fax (888) 267-3277.
- Configure system to require Statement of Medical Necessity (SMN) precertification forms for all omalizumab requests in applicable plan designs.
- Update prior authorization workflows to validate prescriber specialty matches the approved indication: allergist/immunologist or pulmonologist (asthma), allergist/immunologist or otolaryngologist (CRSwNP), allergist/immunologist or dermatologist (urticaria), allergist/immunologist (food allergy), dermatologist/hematologist/oncologist (checkpoint inhibitor toxicity), or allergist/immunologist/dermatologist/hematologist/oncologist (systemic mastocytosis).
- For asthma and urticaria cases, update authorization forms to require documentation of baseline serum IgE ≥30 IU/mL (asthma) or up-dosed H1 antihistamine trial ≥2 weeks (urticaria) BEFORE omalizumab approval.
- For CRSwNP, configure system to verify member has nasal polyp documentation (endoscopy, rhinoscopy, or CT showing polyps below middle turbinate) plus Meltzer score ≥2 or NPS ≥5 with min 2 per nostril before authorizing.
- For food allergy, ensure claims documentation includes allergen-specific IgE or skin-prick test confirmation plus either positive oral food challenge or systemic reaction history.
- Ensure all authorization denials cite specific unmet criteria (e.g., "Member age <6 years" for asthma, "Inadequate prior biologic trial" for continuation therapy).
- Claims submitted without precertification or with incomplete medical necessity documentation will be DENIED.
- Billing team should flag to providers that prior biologic therapy (Nucala, Cinqair, Dupixent as applicable per indication) within past 12 months provides expedited pathway to omalizumab approval.
- Front desk staff must update patient financial counseling to include precertification timeline (allow 2-3 business days minimum).